El objetivo de este estudio clínico es proporcionar acceso continuo al(los) medicamento(s) del estudio a niños y adolescentes con virus de inmunodeficiencia humana tipo 1 (VIH-1) que completaron su participación en un estudio principal aplicable, y monitorear la aparición de eventos adversos. Los objetivos primarios de este estudio son los siguientes: * Proporcionar acceso continuo al medicamento del estudio recibido en el protocolo principal o cambiar a bictegravir/emtricitabina/tenofovir alafenamida (B/F/TAF) para los participantes que completaron un estudio principal de Gilead que evaluaba fármacos para el tratamiento del VIH. * Evaluar la seguridad del(los) medicamento(s) del estudio en participantes con VIH-1.
200/25 mg fixed-dose combination (FDC) tablet administered orally
200/10 mg FDC tablet administered orally
120/15 mg FDC tablet administered orally
60/7.5 mg tablet for oral suspension (TOS) administered orally
30/3.75 mg TOS administered orally
15/1.88 mg TOS administered orally
150/150/200/10 mg tablet administered orally
90/90/120/6 mg tablet administered orally
150 mg tablet administered orally
90 mg tablet administered orally
30 mg TOS administered orally
50/200/25 mg FDC tablet administered orally
30/120/15 mg FDC tablet administered orally
15/60/7.52 mg TOS administered orally
7.5/30/3.76 mg TOS administered orally
3.76/15/1.88 mg TOS administered orally
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country
NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
Administered according to the prescribing information
Administered according to the prescribing information
Administered according to the prescribing information
Buenos Aires, Argentina
CONTACT